ESTRO 2024 - Abstract Book

S2543

Clinical - Urology

ESTRO 2024

Finally, we cannot ignore the very low number of men with known ethnic minority origin (3%), compared with men known to be white (54%). Without reliable data records, research towards better and personalised treatments across all ethnic populations remain hampered.

Keywords: prostate, ethnicity, radiotherapy

References:

1. El Khoury, C. J. & Clouston, S. A. P. Racial/Ethnic Disparities in Prostate Cancer 5-Year Survival: The Role of Health-Care Access and Disease Severity. Cancers (Basel). 15, (2023).

2. Delon, C. et al. Differences in cancer incidence by broad ethnic group in England, 2013 – 2017. Br. J. Cancer 2022 12612 126, 1765 – 1773 (2022).

3. Maruthappu, M., Barnes, I., Sayeed, S. & Ali, R. Incidence of prostate and urological cancers in England by ethnic group, 2001-2007: A descriptive study. BMC Cancer 15, 1 – 12 (2015).

4. Mchugh, J. et al. Prostate cancer risk in men of differing genetic ancestry and approaches to disease screening and management in these groups. doi:10.1038/s41416-021-01669-3.

5.

ETHNIC

CATEGORY

CODE

2001.

https://www.datadictionary.nhs.uk/attributes/ethnic_category_code_2001.html.

6. Ekanger, C. et al. Ten-Year Results From a Phase II Study on Image Guided, Intensity Modulated Radiation Therapy With Simultaneous Integrated Boost in High-Risk Prostate Cancer. Adv. Radiat. Oncol. 5, 396 – 403 (2020).

7. Shortall, J. et al. Dose outside of the prostate is associated with improved outcomes for high-risk prostate cancer patients treated with brachytherapy boost. Front. Oncol. 13, (2023).

2508

Digital Poster

Prostate SBRT delivered with 1.5T MR-linac or Cyberknife: a propensity score matching analysis

Luca Nicosia 1 , Lucas Mose 2 , Michele Rigo 1 , Andrea Gaetano Allegra 1 , Daniel M Aebersold 2 , Filippo Alongi 1

1 IRCCS Sacro Cuore Don Calabria Cancer Care Center, Department of Advanced Radiation Oncology, Negrar, Italy. 2 Inselspital Bern, University of Bern, Department of Radiation Oncology, Bern, Switzerland

Purpose/Objective:

To compare acute and late toxicity of prostate cancer (PCa) stereotactic body radiotherapy (SBRT) delivered by daily adaptive MR-guided radiotherapy (MRgRT) with 1.5T MR-linac or robotic SBRT with CyberKnife.